[1/19] Could Omicron be the calm before antibody dependent enhancement (ADE) induces a devastating mass cytokine storm? Dr Vanden Bossche’s (@GVDBossche) new white paper hypothesises a tragic evolutionary pathway the virus may now be forced into due to our “vaccine” foolishness. [2/19] GVB characterises Omicron’s two defining characteristics:
i) high infectivity rate with the virus confined to the upper respiratory tract
ii) low virulence (mild symptoms) due to inefficient pulmonary infection

GVB then suggests how the next class of variants may emerge.

[1/9] This is the untold and shocking story of Pfizer’s 12-to-15-year-old clinical trial. Just 2264 adolescents were randomised between October 2020 and January 2021. I will describe the various related, serious and life-threatening injuries sustained by these youngsters. [2/9] 1180 of these youngsters received at least one 30μg dose before the data cutoff date, 13 March 2021, comprised of 1131 adolescents during the blinded study and 49 from the placebo group, who turned 16, were unblinded and chose to be treated under the FDA’s recent 16+ EUA.